ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HRS8179

A development code. Also written as “HRS8179 injection”.

Its studies are mostly in Brain Edema, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Dec 10, 20242 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine21 open or runningphase 3since Dec 10, 2024Dec 27, 2022Jun 2027phase 3 · NCT06732648

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 27, 2022First study: phase 2 study in Brain EdemaFirst studyNCT05690711 · 40 enrolled · China
  2. Dec 10, 2024Phase 3 study in Severe Cerebral Edema Following Large Hemispheric InfarctionNCT06732648 · 725 planned · China

Ahead

  1. Jun 2027Primary completion: phase 3 study in Severe Cerebral Edema Following Large Hemispheric InfarctionNCT06732648

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06732648Severe Cerebral Edema Following Large Hemispheric Infarction · China3RecruitingJun 2027725
NCT05690711Brain Edema · China2CompletedDec 5, 202340

How it is read

Names in the registry

  • “HRS8179 injection”, 1 entry
  • “HRS8179”, 1 entry

Codes read as this program: HRS8179.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.